Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 565M | 5.1% |
| Gross Profit | 736M | 172.3% |
| Cost of Revenue | -171M | 164% |
| Operating expense | 57M | 3.6% |
| Net Income | 544M | 433.3% |
| EBITDA | 735M | 172.6% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 18B | 2.2% |
| Total Liabilities | 7.78B | 1.5% |
| Total Equity | 10.3B | 5.2% |
| Shares Outstanding | 448M | 0.8% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | 704M | 6.9% |
| Cash from investing | -1.19B | 33.5% |
| Cash from financing | -326M | 128.1% |
EPS
Financial Highlights for Royalty Pharma in Q3 '24
Royalty Pharma reported a revenue of 565M, which is a 5.1% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 736M, marking a 172.3% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was -171M, a -164% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 57M, showing a 3.6% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 544M, showing a 433.3% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 735M, showing a 172.6% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Royalty Pharma with growth in revenue, gross profit, and net income. Higher operating expenses might indicate increased investments or potential inefficiencies.
